Accurate intervention study on the residual risk in post-ACS with carotid plaque disease by xinnaoning capsule

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025832

Enrollment

Unknown

Registered

2019-09-10

Start date

2019-09-10

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the residual risk of Post- acute coronary syndrome state complicated with carotid artery plaque

Interventions

intervertion:Basic treatment and Xin-Nao-Ning capsule

control:Basic treatment and Xin-Nao-Ning capsuleplacebo

Eligibility

Sex/Gender

All

Age

30 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Age range from 45 to 79 years, regardless of gender. 2. 15-90 days after the occurrence of acute coronary syndrome (ACS) requiring hospitalization, coronary heart disease was diagnosed by imaging. 3. CCS II~III labor angina pectoris which has been treated with combination anti-angina medication but cannot been completely controlled. Note: Anti-angina drugs include beta blockers, long-acting nitrates, calcium antagonists. 4. Non-calcified carotid plaques can be found by carotid ultrasound detection (definition: localized thickening of the medial epithelium in either the common carotid artery or internal carotid artery wall on the left or right>=1.3mm and <=3.5mm, no significant calcification ). 5. High-sensitivity C-reactive protein (hs-CRP) 2~10mg/L. 6. Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. History of stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, and unexplained stroke) or symptomatic lower limbs arteriosclerosis occlusion disease in the past 6 months. 2. Uncontrolled grade 3 hypertension (>=180/100mmHg) or hypotension (= 2 times the clinical reference limit), other serious primary disease or mental disease and malignant tumor which affecting life expectancy. 8. The investigator judges that there may be other conditions or contraindications that may affect the research.

Design outcomes

Primary

Measure	Time frame
DCG;hs-CRP;	—

Secondary

Measure	Time frame
Weekly angina attacks;Weekly use of nitroglycerin and its reduction rate;SAQ;EQ-5D;	—

Countries

China

Contacts

Public ContactLu Feng

Affiliated Hospital of Shandong University of TCM

wangjianlufeng@163.com+86 13305311796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026